European Academy of Neurology (EAN) Congress 2026

Geneva, Switzerland 27 June 2026 - 30 June 2026

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026 by

Nearly a third of glioblastoma patients treated with standard radiotherapy plus temozolomide (STUPP protocol) suffer early-onset radiation induced leukoencephalopathy (RIL), which is linked to early cognitive and functional decline, according to a study.

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026 by

The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026

Does MS relapse after stopping ponesimod?

17 Jul 2026 by

In a post hoc analysis of the OPTIMUM* long-term extension (OPTIMUM-LTE) study, discontinuation of ponesimod did not lead to a clinically meaningful disease reactivation or rebound effect in patients with relapsing multiple sclerosis (MS).

Does MS relapse after stopping ponesimod?

17 Jul 2026

Functional outcome improvements with atogepant sustained until 3 years

15 Jul 2026 by

A 156-week safety extension study presented at EAN 2026 shows the first 3-year long-term results for atogepant in the preventive treatment of migraine in individuals with chronic migraine (CM) or episodic migraine (EM) who had an insufficient response to 2–4 classes of conventional oral, non-migraine-specific preventive migraine treatments.

Functional outcome improvements with atogepant sustained until 3 years

15 Jul 2026

Switching DOACs after a breakthrough stroke provides no additional benefit

28 May 2026 by

For patients with atrial fibrillation (AF) who sustained an ischaemic stroke while receiving direct oral anticoagulant (DOAC) therapy, switching to another anticoagulation agent does not yield significant improvements in most clinical outcomes compared with staying on the same agent, according to the results of an emulated target trial.

Switching DOACs after a breakthrough stroke provides no additional benefit

28 May 2026